Literature DB >> 20736236

Lack of EP4 receptors on bone marrow-derived cells enhances inflammation in atherosclerotic lesions.

Eva H C Tang1, Koichi Shimizu, Thomas Christen, Viviane Z Rocha, Eugenia Shvartz, Yevgenia Tesmenitsky, Galina Sukhova, Guo-Ping Shi, Peter Libby.   

Abstract

AIM: prostaglandin E(2), by ligation of its receptor EP4, suppresses the production of inflammatory cytokines and chemokines in macrophages in vitro. Thus, activation of EP4 may constitute an endogenous anti-inflammatory pathway. This study investigated the role of EP4 in atherosclerosis in vivo, and particularly its impact on inflammation. METHODS AND
RESULTS: Ldlr(-/-) mice transplanted with EP4(+/+) or EP4(-/-) bone marrow consumed a high-fat diet for 5 or 10 weeks. Allogenic bone marrow transplantation promoted exacerbation of atherosclerosis irrespective of EP4 genotype, compatible with prior observations of exacerbated atherogenesis by allogenicity. EP4 deficiency had little effect on plaque size or morphology in early atherosclerosis, but at the later time point, mice deficient in EP4 displayed enhanced inflammation in their atherosclerotic plaques. Expression of monocyte chemoattractant protein-1 and interferon-γ inducible protein 10 increased, and there was a corresponding increase in macrophage and T-cell infiltration. These plaques also contained fewer smooth muscle cells. Despite these changes, mice deficient in EP4 in bone marrow-derived cells at an advanced stage had similar lesion size (in both aorta and aortic root) as mice with EP4.
CONCLUSION: this study shows that in advanced atherosclerosis, EP4 deficiency did not alter atherosclerotic lesion size, but yielded plaques with exacerbated inflammation and altered lesion composition.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20736236      PMCID: PMC3002867          DOI: 10.1093/cvr/cvq262

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  30 in total

1.  Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury.

Authors:  Keiichi Hishikari; Jun-ichi Suzuki; Masahito Ogawa; Kazuya Isobe; Teisuke Takahashi; Michihito Onishi; Kiyoshi Takayama; Mitsuaki Isobe
Journal:  Cardiovasc Res       Date:  2008-09-18       Impact factor: 10.787

Review 2.  Cyclooxygenase-2 inhibitors: a painful lesson.

Authors:  Sandhya Sanghi; Eric J MacLaughlin; Coty W Jewell; Sheldon Chaffer; Peter J Naus; Linley E Watson; David E Dostal
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2006-06

3.  A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling.

Authors:  Kiyoshi Takayama; Galina K Sukhova; Michael T Chin; Peter Libby
Journal:  Circ Res       Date:  2006-01-19       Impact factor: 17.367

Review 4.  The specific role of chemokines in atherosclerosis.

Authors:  Vincent Braunersreuther; François Mach; Sabine Steffens
Journal:  Thromb Haemost       Date:  2007-05       Impact factor: 5.249

5.  Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis.

Authors:  Vladimir R Babaev; Joshua D Chew; Lei Ding; Sarah Davis; Matthew D Breyer; Richard M Breyer; John A Oates; Sergio Fazio; Macrae F Linton
Journal:  Cell Metab       Date:  2008-12       Impact factor: 27.287

6.  Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activation.

Authors:  Manabu Minami; Koichi Shimizu; Yoshihisa Okamoto; Eduardo Folco; Marco-Lopez Ilasaca; Mark W Feinberg; Masanori Aikawa; Peter Libby
Journal:  J Biol Chem       Date:  2008-02-12       Impact factor: 5.157

7.  Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice.

Authors:  Daiju Fukuda; Masataka Sata; Nobukazu Ishizaka; Ryozo Nagai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-25       Impact factor: 8.311

Review 8.  Apoptosis and efferocytosis in mouse models of atherosclerosis.

Authors:  Ira Tabas
Journal:  Curr Drug Targets       Date:  2007-12       Impact factor: 3.465

9.  Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice.

Authors:  Jiusong Sun; Galina K Sukhova; Min Yang; Paul J Wolters; Lindsey A MacFarlane; Peter Libby; Chongxiu Sun; Yadong Zhang; Jian Liu; Terri L Ennis; Rebecca Knispel; Wanfen Xiong; Robert W Thompson; B Timothy Baxter; Guo-Ping Shi
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

10.  Matrix-metalloproteinase-14 deficiency in bone-marrow-derived cells promotes collagen accumulation in mouse atherosclerotic plaques.

Authors:  Fabrice Schneider; Galina K Sukhova; Masanori Aikawa; James Canner; Norbert Gerdes; Sai-Man Timothy Tang; Guo-Ping Shi; Suneel S Apte; Peter Libby
Journal:  Circulation       Date:  2008-02-04       Impact factor: 29.690

View more
  23 in total

1.  Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis.

Authors:  Constantin von zur Muhlen; Eric Schiffer; Christine Sackmann; Petra Zürbig; Irene Neudorfer; Andreas Zirlik; Nay Htun; Alexander Iphöfer; Lothar Jänsch; Harald Mischak; Christoph Bode; Yung C Chen; Karlheinz Peter
Journal:  Mol Cell Proteomics       Date:  2012-02-27       Impact factor: 5.911

2.  Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE2 (Prostaglandin E2) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury.

Authors:  Huifeng Hao; Sheng Hu; Qing Wan; Chuansheng Xu; Hong Chen; Liyuan Zhu; Zhenyu Xu; Jian Meng; Richard M Breyer; Nailin Li; De-Pei Liu; Garret A FitzGerald; Miao Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-03-29       Impact factor: 8.311

Review 3.  Cardiovascular biology of microsomal prostaglandin E synthase-1.

Authors:  Miao Wang; Garret A FitzGerald
Journal:  Trends Cardiovasc Med       Date:  2010-08       Impact factor: 6.677

4.  The fish oil ingredient, docosahexaenoic acid, activates cytosolic phospholipase A₂ via GPR120 receptor to produce prostaglandin E₂ and plays an anti-inflammatory role in macrophages.

Authors:  Yueqin Liu; Li-Yuan Chen; Milena Sokolowska; Michael Eberlein; Sara Alsaaty; Asuncion Martinez-Anton; Carolea Logun; Hai-Yan Qi; James H Shelhamer
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

Review 5.  Inflammation and its resolution as determinants of acute coronary syndromes.

Authors:  Peter Libby; Ira Tabas; Gabrielle Fredman; Edward A Fisher
Journal:  Circ Res       Date:  2014-06-06       Impact factor: 17.367

Review 6.  Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases.

Authors:  Eva H C Tang; Peter Libby; Paul M Vanhoutte; Aimin Xu
Journal:  J Cardiovasc Pharmacol       Date:  2012-02       Impact factor: 3.105

Review 7.  Prostaglandins and inflammation.

Authors:  Emanuela Ricciotti; Garret A FitzGerald
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-05       Impact factor: 8.311

8.  Matrix metalloproteinase-dependent microsomal prostaglandin E synthase-1 expression in macrophages: role of TNF-α and the EP4 prostanoid receptor.

Authors:  K M Faisal Khan; Poonam Kothari; Baoheng Du; Andrew J Dannenberg; Domenick J Falcone
Journal:  J Immunol       Date:  2012-01-06       Impact factor: 5.422

9.  Activation of prostaglandin E2-EP4 signaling reduces chemokine production in adipose tissue.

Authors:  Eva H C Tang; Yin Cai; Chi Kin Wong; Viviane Z Rocha; Galina K Sukhova; Koichi Shimizu; Ge Xuan; Paul M Vanhoutte; Peter Libby; Aimin Xu
Journal:  J Lipid Res       Date:  2014-12-15       Impact factor: 5.922

10.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.